DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
NCT06749210
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cancer of the Breast
- Chemotherapy-induced Neuropathy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Last updated on ClinicalTrials.gov
- October 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Yale University · New Haven, CT
Ohio · 1
- The Ohio State University · Columbus, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.